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Abstract
Introduction: Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones
for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast
cancer. The expression of Hsp27, an ATP-independent small HSP, is associated with cell migration and drug
resistance of breast cancer cells. Breast cancer stem cells (BCSCs) have been identified as a subpopulation of breast
cancer cells with markers of CD24-CD44+ or high intracellular aldehyde dehydrogenase activity (ALDH+) and
proved to be associated with radiation resistance and metastasis. However, the involvement of Hsp27 in the
maintenance of BCSC is largely unknown.
Methods: Mitogen-activated protein kinase antibody array and Western blot were used to discover the expression
of Hsp27 and its phosphorylation in ALDH + BCSCs. To study the involvement of Hsp27 in BCSC biology, siRNA
mediated gene silencing and quercetin treatment were used to inhibit Hsp27 expression and the characters of
BCSCs, which include ALDH+ population, mammosphere formation and cell migration, were analyzed
simultaneously. The tumorigenicity of breast cancer cells after knockdown of Hsp27 was analyzed by
xenograftment assay in NOD/SCID mice. The epithelial-mesenchymal transition (EMT) of breast cancer cells was
analyzed by wound-healing assay and Western blot of snail, vimentin and E-cadherin expression. The activation of
nuclear factor kappa B (NF-B) was analyzed by luciferase-based reporter assay and nuclear translocation.
Results: Hsp27 and its phosphorylation were increased in ALDH+ BCSCs in comparison with ALDH- non-BCSCs.
Knockdown of Hsp27 in breast cancer cells decreased characters of BCSCs, such as ALDH+ population,
mammosphere formation and cell migration. In addition, the in vivo CSC frequency could be diminished in Hsp27
knockdown breast cancer cells. The inhibitory effects could also be observed in cells treated with quercetin, a plant
flavonoid inhibitor of Hsp27, and it could be reversed by overexpression of Hsp27. Knockdown of Hsp27 also
suppressed EMT signatures, such as decreasing the expression of snail and vimentin and increasing the expression
of E-cadherin. Furthermore, knockdown of Hsp27 decreased the nuclear translocation as well as the activity of NF-
B in ALDH + BCSCs, which resulted from increasing expression of IBa. Restored activation of NF-Bb y
knockdown of IBa could reverse the inhibitory effect of Hsp27 siRNA in suppression of ALDH+ cells.
Conclusions: Our data suggest that Hsp27 regulates the EMT process and NF-B activity to contribute the
maintenance of BCSCs. Targeting Hsp27 may be considered as a novel strategy in breast cancer therapy.
* Correspondence: changww@csmu.edu.tw
4School of Biomedical Sciences and Department of Medical Research, Chung
Shan Medical University, Chien-Kuo N. Rd., Sec. 1, No.110, Taichung City, 402,
Taiwan
Full list of author information is available at the end of the article
Wei et al. Breast Cancer Research 2011, 13:R101
http://breast-cancer-research.com/content/13/5/R101
© 2011 Wei et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Heat shock proteins (HSPs) are a group of proteins that
were first discovered under heat shock or other chemical
stimulus in a wide range of species and function as mole-
cular chaperones that can interact with their substrates to
shift the balance from denatured protein conformation
toward functional conformation [1]. Besides their chaper-
one function, HSPs have been reported to be overex-
pressed in various cancers and to display a correlation
with patients’ survival or response to therapy in specific
cancer types and may serve as novel therapeutic targets
[2]. Hsp27 belongs to a small HSP family and has been
found to contribute to the malignant properties of cancer
cells, including increased tumorigenicity, treatment resis-
tance and apoptosis inhibition [3]. In breast cancer, Hsp27
has been reported as a risk factor of malignant progression
in benign proliferating breast lesions [4] and its expression
could help to differentiate benign and malignant breast
lesions in fine needle aspirate [5]. Hsp27 has been reported
to be associated with drug resistance and cell mobility
properties of breast cancer. In the Herceptin-resistant
SKBR3 breast cancer cell line, silencing of Hsp27 expres-
sion by siRNA increased the susceptibility to Herceptin
treatment through decreasing Her2 protein stability [6].
Overexpression of Hsp27 also protected MDA-MB-231
breast cancer cells from doxorubicin induced apoptosis
[7]. Inhibition of Hsp27 phosphorylation with a small
molecule inhibitor also suppressed the cell invasion capa-
city of metastatic MDA-MB-231 cells [8]. Although Hsp27
is involved in chemoresistance and invasion phenotypes of
breast cancer cell lines, the involvement of Hsp27 in breast
cancer stem cells (BCSCs) is not fully understood.
Cancer stem cells, which are a particular subset of can-
cer cells responsible for tumorigenesis, chemoresistance
and metastasis, are emerging targets in cancer research
[9]. In breast cancer, BCSCs have been identified as cells
with surface markers of CD24-CD44+ [10] or high intra-
cellular aldehyde dehyprogenase activity (ALDH+) [11].
Recently, Hsp27 has been proven to contribute to the
drug resistance property of lung cancer stem cells [12].
The expression of Hsp27 was increased in lung CSCs trea-
ted with cisplatin/gemcitabine. A combination of che-
motherapy with a plant flavonoid compound quercetin,
which can inhibit Hsp27 expression, could suppress the
tumor growth as well as the expression of stemness genes,
including Oct4, Nanog and Sox2 [12]. Quercetin could also
sensitize epigallocathechin gallate to inhibit the spheroid
formation, cell survival and invasion of CD44+ CD133+
prostate cancer stem cells [13], although the detailed
molecular mechanisms remains unknown.
In the present study, we identified that the expression of
Hsp27 and its phosphorylation were increased in ALDH+
BCSCs. Inhibition of Hsp27 by siRNA or quercetin, a
plant flavonoid compound, suppressed characters of
BCSCs, including ALDH+ population, mammosphere for-
mation and epithelial-mesenchymal transition (EMT). We
also found that Hsp27 could regulate the NF-kB activity of
BCSCs. These findings suggest that Hsp27 regulates the
maintenance of BCSCs and it may serve as a potential tar-
get in future breast cancer therapy.
Materials and methods
Cell culture and reagents
AS-B145 and AS-B244 breast cancer cells, which derived
from BC0145 or BC0244 xenograft human breast cancer
cells [14], were cultured in MEMa supplemented with
10% fetal bovine serum, bovine insulin (0.1 mg/mL),
sodium pyruvate (1 mM), and Glutamax (2 mM). 4T1
mouse breast cancer cells and an MDA-MB-231 human
breast cancer cell line were obtained from ATCC (Mana-
ssas, VA, USA) and cultivated as ATCC’s recommenda-
tion. The cells were maintained in a 5% CO2 air
humidified atmosphere at 37°C. Quercetin and JSH-23
were purchased from Calbiochem (San Diego, CA, USA)
and dissolved in dimethyl sulfoxide (DMSO). pDsRed-
Express2-C1 vector was purchased from Clontech
(Mountain View, CA, USA). To construct DsRed tagged
Hsp27, the Hsp27 gene was cloned from AS-B145 cDNA
by the following primers: 5’-CACTTGAGATCTACC-
GAGCGCCGCGTCCCCTTC-3’ (forward); 5’-CAAGTG-
GAATTCTTACTTGGCGGCAGTCTCATC-3’ (reverse)
and inserted into pDsRed-Express2-C1 vector by BglII
and EcoRI restriction sites (pDsRed-Hsp27).
Antibody array and Western blot
MAPK antibody array was purchased from R&D Systems
(Minneapolis, MN, USA) and conducted following the
manufacturer’s protocol. Briefly, the membrane was
blocked in blocking buffer and incubated with 150 μgo f
total cellular protein and detection antibody simulta-
neously at 4°C overnight. After washing, the membrane
was further incubated with streptavidin-HRP at room tem-
perature for 30 minutes and a signal was developed with
ECL substrate. For Western blot, cells were lysed with
NP-40 lysis buffer and 25 μg of total protein were sepa-
rated by SDS-PAGE and transferred to polyvinylidene
fluoride membrane. Protein detection was conducted by
SignalBoost™ Immunodetection Enhancer kit (Calbio-
chem) according to the manufacturer’s recommendation.
Hsp27 antibody was purchased from Stressgen (Ann
Arbor, MI, USA). IBa and phosphor-IBa antibodies
were purchased from Cell Signaling Technologies (Boston,
MA, USA). NF-B p65 antibody was purchased from
Millipore (Billerca, MA, USA). Snail, twist, vimentin,
GAPDH and histone H1 antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). b-actin
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CO, USA).
RNA interference and Hsp27 overexpression
The specific siRNA oligos of Hsp27 (sc-29350) or IBa
(sc-29360), or negative control siRNA oligos was pur-
chased from Santa Cruz Biotechnologies, Inc. The siRNA
oligos of Hsp27 or IBa consisted of pools of three target-
specific siRNAs designed to knockdown gene expression
and the target sequences were listed below:
sc-29350A: Sense: GAGUGGUCGCAGUGGUUAGtt;
Antisense: CUAACCACUGCGACCACUCttsc-29350B:
Sense: GACGAGCUGACGGUCAAGAtt; Antisense:
UCUUGACCGUCAGCUCGUCttsc-29350C: Sense: CCA
CGCAGUCCAACGAGAUtt; Antisense: AUCUCGUU
GGACUGCGUGGtt
sc-29360A: Sense: CCACACGUGUCUACACUUAtt;
Antisense: UAAGUGUAGACACGUGUGGttsc-29360B:
Sense: GACGAGAAAGAUCAUUGAAtt; Antisense:
UUCAAUGAUCUUUCUCGUCttsc-29360C: Sense:
CCUGUCAAGGUUUGUGUUAtt; Antisense: UAACA-
CAAACCUUGACAGGttMetafecteneSI transfection
reagent (Biontex, Martinsired, Germany) was used for
siRNA transfection following the manufacturer’sp r o t o -
col. To overexpress Hsp27, cells were transfected with
pDsRed-Hsp27 by MetafectenePro transfection reagent
(Biontex) as a ratio (DNA (μg):reagent (μl)) of 1:3.
ALDEFLUOR assay
An ALDEFLUOR assay kit was purchased from StemCell
Technologies, Inc. (Vancouver, BC, Canada) and used fol-
lowing the manufacturer’s recommendations. Briefly, 1 ×
10
5 cells were suspended in 50 μl of assay buffer and
added to BODIPY-aminoacetaldehyde substrate to a final
concentration of 1 μM. For ALDH1 inhibitor control,
diethylaminobenzaldehyde (DEAB) was added to the final
concentration of 150 μM. Cells were then incubated at
37°C for 45 minutes and stained with 7-AAD on ice for a
further 5 minutes. After being washed with PBS, green
fluorescence positive cells in live cells (7AAD-) were ana-
lyzed by flow cytometry (Epics XL, Beckman Coulter,
Brea, CA, USA) by comparing the fluorescence intensity
of the DEAB treated sample; these cells will be represented
as cells with high ALDH activity (ALDH+ cells).
Mammosphere culture
Cells were harvested from monolayer culture or collected
by fluorescence-activated cell sorting (FACS) and prepared
at a density of 1 × 10
4 cells/ml in DMEM/F12 medium
contain 0.5% methylcellulose, 0.4% bovine serum albumin,
10 ng/ml EGF, 10 ng/ml bFGF, 5 μg/ml insulin, 1 μM
hydrocortisone and 4 μg/ml heparin. A total of 2 ml of
cell solution was seeded into wells of ultralow attachment
six-well-plate (Corning, Lowell, MA, USA) and incubated
for seven days. For secondary spheres, the cells were col-
lected from accutase treated primary spheres, seeded at a
density of 2,500 cells/ml and cultivated for a further seven
days.
Xenograftment assay in NOD/SCID mice
The tumorigenicity of AS-B145 sphere cells was examined
by xenograftment assay in NOD/SCID mice. After trans-
fection with ctrl-siRNA or si-Hsp27 for 48 h, an indicated
number of AS-B145 cells was mixed with 10
5 normal
breast fibroblasts by 50 μlo fM E M a:matrigel (1:1) (BD
Biosciences, San Jose, CA, USA) and injected into mam-
mary fat pads of female NOD/SCID mice (BioLASCO Tai-
wan Co., Ltd. Taipei, Taiwan). The tumor formation was
monitored weekly. The CSC frequency was calculated by
Extreme Limiting Dilution Assay (Walter-Eliza Hall Bioin-
formatics, Bundoora Victoria, Australia.) [15].
Cell migration assay
A cell migration assay was conducted by Oris Universal
Cell Migration Assembly kit (Platypus Technologies, LCC,
Madison, WI, USA) following the manufacturer’sp r o t o c o l .
Briefly, 5 × 10
4 cells/well/100 μl were loaded into stopper-
loaded wells and incubated overnight to permit cell attach-
ment. To start cell migration, the stoppers were removed;
wells were gently washed with PBS, then added to com-
plete cell culture medium and incubated for 16 to 18 h.
Pictures of wells were captured with inverted microscopy
after fixation and stain with 0.5% crystal violet/50% EtOH.
Data were analyzed with ImageJ software (National Health
Institute, Bethesda, MD, USA).
NF-kB reporter assay
The luciferase based NF-B reporter vector was obtained
from Stratagene (Santa Clara, CA, USA). The assay was
conducted with a dual reporter assay system. Briefly, the
NF-B vector was co-transfected with reference Renilla
luciferase vector (Promega, Madison, WI, USA) ast a ratio
of 10:1. After transfection for 48 h, cells were lysed by pas-
sive lysis buffer (Promega) and luciferase activity was
detected with Beetle-Juice (for firefly luciferase (FLuc))
and Gaussia-Juice (for Renilla luciferase (RLuc)) substrates
(PJK GmbH, Kleinblittersdorf, Germany) and lumines-
cence was counted with luminescence reader (Promega).
The results of FLuc count were normalized with RLuc,
which represented the transfection efficiency of each
sample.
Results
Up-regulation of Hsp27 and its phosphorylation in breast
cancer stem cells
We have previously established two human breast cancer
cells from xenografts of NOD/SCID mice and identified
that cells with high intracellular aldehyde dehydrogenase
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activity, proteins extracted from ALDH- or ALDH+ cells
of BC0145 or BC0244 xenografts were subjected to mito-
gen activated protein kinase (MAPK) antibody array and
results indicated that the activation of Akt, ERK, p38
MAPK and RSK1 were increased in BSCSs (Additional file
1 Figures S1 and S2). The phosphorylation of Hsp27,
which may result from p38 MAPK activity, was also
increased in ALDH+ BCSCs from BC0145 or BC0244
xenograft cells (Figure 1A). We also used Western blot to
check the level of total Hsp27 protein between ALDH-
and ALDH+ AS-B244 cells, which derived from ALDH+
BC0244 xenograft cells [14]. As shown in Figure 1B, the
total protein level of Hsp27 was higher in ALDH+ cells
than in ALDH- cells. These results indicate that Hsp27and
its phosphorylation are up-regulated in BCSCs.
Hsp27 determines the maintenance of breast cancer stem
cells as well as their characteristics of epithelial-
mesenchymal transition
We next investigated the role of Hsp27 in maintenance
of BCSCs by siRNA mediated gene silence of Hsp27
expression. After transfection with Hsp27 specific
siRNA, the population of ALDH+ cells in AS-B145 or
AS-B244 cells was significantly decreased to (50.2 ±
12.2)% or (58.7 ± 3.5)%, respectively, when compared
with cells transfected with negative control siRNA
(Figure 2A). Knockdown of Hsp27 not obviously caused
cell death (less than 22% of all time points) and slowed
the cell growth rate of AS-B145 cells (Additional file 1
Figure S3A, C), but caused obvious cell death (35% and
65% at 72 h and 96 h, respectively) and decreased cell
number at 72 h and 96 h in AS-B244 cells (Additional
file 1 Figure 3B, D). Other than the ALDH+ population
of cells, the number of mammospheres as well as the
size of formed spheres in AS-B145 or AS-B244 cells
were also decreased (Figure 2B). We further examined if
Hsp27 was involved in the tumorigenicity of BCSCs.
AS-B145 sphere cells were collected for seven days after
mammosphere culture, transfected with negative control
siRNA or Hsp27 specific siRNA for 48 h and injected
into mammary fat pads of female NOD/SCID mice in a
serial dilution of injected cell number. As shown in Fig-
ure 2C, 10
5 negative control siRNA transfected AS-B145
Figure 1 Increased expression of Hsp27 in ALDH+ BCSCs.( A) ALDH- or ALDH+ cells were sorted from BC0145 and BC0244 xenografts and
150 μg of extracted total protein were subjected into PVDF membrane of MAPK array as described in “Materials and methods” section. P-Hsp27,
phosphorylated Hsp27; p-p38 MAPK, phosphorylated p38 MAPK. (B) ALDH- or ALDH+ cells were sorted from AS-B244 cells and 25 μg of total
protein were used for Hsp27 or GAPDH detection by Western blot. Inserted values indicated relative expression of Hsp27 in ALDH- or ALDH+
cells. ALDH, aldehyde dehydrogenase; MAPK, mitogen activated protein kinase.
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Page 4 of 13Figure 2 Knockdown of Hsp27 decreased BCSCs of breast cancer cells.( A) AS-B145 cells were transfected with Hsp27 siRNA (si-Hsp27) or
negative control siRNA (ctrl-siRNA) for 48 h and detected a ALDH+ population by ALDEFLUOR assay. The percentage of ALDH+ cells were
calculated from samples without DEAB treatment (w/o DEAB) after gating with a cutoff line which was set according to DEAB treated (w/DEAB)
cells. The quantitative results were presented as relative percentage of ctrl siRNA transfected cells. *, P < 0.05. (B) Primary (1
st) mammosphere
formation capacity of AS-B145 or AS-B244 cells was also analyzed after knockdown of Hsp27 for 48 h. For secondary (2
nd) mammosphere
cultivation, 1
st spheres were collected, digested with accutase and subjected to mammosphere cultivation at 48 h post-transfected with si-Hsp27
or negative control siRNA (ctrl-siRNA). Data were collected at Day 7 post starting the cultivation and presented as relative percentage of ctrl
siRNA. Bar, 100 μm. #, P < .01; *, P < 0.05. (C) The tumorigenicity of AS-B145 sphere cells after knockdown of Hsp27 (si-Hsp27) or negative
control siRNA (ctrl-siRNA) was determined by xenograftment assay in NOD/SCID mice. The indicated numbers of cells were injected into
mammary fat pads for 44 days and the tumor formation was monitored weekly. The cancer stem cell (CSC) frequency was calculated with ELDA
software [15]. *, P < 0.05. ALDH, aldehyde dehydrogenase; BCSCs, breast cancer stem cells.
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10
5 Hsp27 knockdown cells only formed tumors in two
out of five mice at Day 44 (Figure 2C, left panel). The
CSC frequency of Hsp27 knockdown AS-B145 sphere
cells was significantly decreased when compared with
negative control siRNA groups (1:30,680 versus
1:146,211, P = 0.0206). In addition to RNA interference,
we also used quercetin, a plant flavonoid compound
which has been reported to suppress the protein level of
Hsp27 [16], to treat AS-B145 and AS-B244 cells. Querce-
tin inhibited the expression of Hsp27 protein (Figure 3A)
as well as the population of ALDH+ cells (Figure 3B) in
both AS-B145 and AS-B244 cells in a dose-dependent
manner (Figure 3C). In order to confirm if the inhibition
effect of quercetin is mediated by down-regulation of
Hsp27, we next overexpressed Hsp27 in AS-B145 cells
and examined the ALDH+ population under quercetin
treatment. As shown in Figure 3D and 3E, the inhibitory
effect of quercetin could be reversed by overexpression of
Hsp27 in AS-B145 cells. We next tested if quercetin also
inhibits the self-renewal of BCSCs by mammosphere for-
mation assay. The size and number of primary and sec-
ondary mammospheres in AS-B145 (Figure 4A) and AS-
B244 (Figure 4B) was suppressed by quercetin in a dose-
dependent manner. In addition to human BCSCs, we also
tested if quercetin could inhibit self-renewal of Sca-1+
4T1 mouse BCSCs [17]. As shown in Figure 4C, querce-
tin decreased primary and secondary mammosphere for-
mation of Sca-1+ 4T1 cells in a dose-dependent manner.
EMT is an important character of cancer stem cells
[18]. We next examined if Hsp27 mediates EMT fea-
tures of BCSCs. With a wound healing based cell migra-
tion assay, the cell migration ability of ALDH+ AS-
B244, AS-B145, MDA-MB-231 and Sca-1+ 4T1 cells
was inhibited by quercetin treatment in a dose-depen-
dent manner (Figure 5A). Furthermore, quercetin
Figure 3 Quercetin dose-dependently decreased Hsp27 expression and ALDH+ population of breast cancer cells.( A) AS-B145 or AS-
B244 cells were treated with quercetin at indicated concentration for 48 h and detected the expression of Hsp27 by Western blot. Inserted
values indicated relative expression of Hsp27 in comparison with DMSO. N, no treatment; D, DMSO. (B, C) ALDH+ population after treatment of
quercetin was determined by ALDEFLUOR assay. The quantitative results were shown in bar graph (C). #, P < 0.01; *, P < 0.05. (D, E) AS-B145
cells were transfected with pDsRed-Express2-C1 (pDsRed) or pDsRed-Hsp27 and treated with 0.1% DMSO or 50 μM quercetin for 48 h. The
transfection efficiency of each group was approximately 40% (upper panel) and red fluorescence positive cells were gated to further analyze
Aldefluor green fluorescence signal (lower panel) by WinMDI software. The quantitative results were shown in bar graph (E). P < 0.01; *, P < 0.05.
ALDH: aldehyde dehydrogenase.
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4 cells/ml of AS-B145 (A),
AS-B244 cells (B) or Sca-1+ 4T1(C) were subjected into primary (1
st) mammosphere culture in present of quercetin (50, 25 or 12.5 μM) or 0.1%
DMSO. For secondary mammosphere (2
nd) cultivation, 1
st spheres were collected, digested by accutase and 5,000 cells/ml were subjected into
mammosphere cultivation in present of quercetin or DMSO. Data were collected at Day 7 after the start of cultivation and presented as a
relative percentage of DMSO. Bar in (A), 100 μm; bar in (B), 50 μm; bar in (C), 200 μm. *, P < 0.05; #, P < 0.01.
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Page 7 of 13Figure 5 Inhibition of Hsp27 suppressed EMT signature of BCSCs.( A) Cell migration ability of AS-B145, ALDH+ AS-B244, MDA-MB-231 or
Sca-1+ 4T1 cells in present of quercetin (Q, 12.5, 25 or 50 μM) or 0.1% DMSO or was analyzed with wound-healing assay. *, P < 0.05; #, P < 0.01.
(B) Cell migration ability of AS-B145, MDA-MB-231 or ALDH+ AS-B244 cells after transfection of Hsp27 siRNA (si-Hsp27) or negative control siRNA
(ctrl siRNA) was analyzed with wound-healing assay. *, P < 0.05; #, P < 0.01. (C) EMT related proteins (E-cadherin, vimentin or snail) of AS-B145 or
ALDH+ AS-B244 cells were analyzed by Western blot. Inserted values indicated relative expression of proteins in negative control siRNA (ctrl) or
si-Hsp27 (KD) transfected cells. ALDH: aldehyde dehydrogenase; BCSCs: breast cancer stem cells; EMT, epithelial-mesenchymal transition.
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N-cadherin and twist but increased E-cadherin expres-
sion in both AS-B145 and ALDH+ AS-B244 cells (Addi-
tional file 1 Figure 4). By siRNA mediated knockdown
of Hsp27, the cell migration capacity of AS-B145,
MDA-MB-231 or ALDH+ AS-B244 cells was also inhib-
ited in comparison with negative control siRNA (Figure
5B). We also investigated if the Hsp27 pathway also reg-
ulates EMT-related molecular signatures. With Western
blot analysis, knockdown of Hsp27 in AS-B145 or
ALDH+ AS-B244 cells decreased the expression of snail
and vimentin and increased the expression of E-cad-
herin (Figure 5C). These results indicate that Hsp27
may regulate self-renewal of BCSCs through manipulat-
ing the EMT process.
Hsp27 contributes to IBa degradation and NF-B
activation in breast cancer stem cells
It has been reported that Hsp27 enhances the degrada-
tion of ubiquitinated proteins by 26S proteasome.
Among these ubiquitinated proteins, phosphorylated
IBa could form a complex with Hsp27 and 26S protea-
some and Hsp27 could enhance NF-B activity by facili-
tating proteasome mediated IBa degradation [19].
Recently, the NF-B pathway has been demonstrated to
participate in mammary tumorigenesis and cancer stem
cell expansion in a transgenic mouse model [20]. We
next examined if Hsp27 regulates NF-B activity in
BCSCs. By siRNA mediated knockdown of Hsp27, the
expression of IBa was increased in both AS-B145 and
ALDH+ AS-B244 cells and its phosphorylation was
decreased (Figure 6A). The nuclear translocation of NF-
B was also inhibited in both AS-B145 and ALDH+ AS-
B244 cells when knockdown of Hsp27 occurred (Figure
6B). In the meantime, we also observed that Hsp27 could
enter into the nucleus (Figure 6B). With a luciferase
based reporter assay, the NF-B activity was decreased in
ALDH+ AS-B244 and AS-B145 cells when knockdown of
Hsp27 occurred (Figure 6C). We next used NF-B inhibi-
tors to examine their effects on BCSCs. In the presence
of JSH-23, a NF-B inhibitor which inhibits the nuclear
translocation of NF-B, the ALDH+ population of
AS-B145 and AS-B244 cells was suppressed in a dose-
dependent manner (Figure 6D). We further examined if
additional activation of NF-B could diminish the inhibi-
tory effect of ALDH+ cells by Hsp27 knockdown. The
increased IBa, which was caused by knockdown of
Hsp27, was suppressed by knockdown of IBa (Figure
7A) and the NF-B activity could be restored in Hsp27
knockdown of AS-B145 or AS-B244 cells (Figure 7B).
The inhibitory effect of ALDH+ cells by Hsp27 knock-
down could be reversed by additional knockdown of
IBa in both AS-B145 and AS-B244 cells (Figure 7C, D).
These results suggest that Hsp27 regulates the mainte-
nance of BCSCs through NF-B activity.
Discussion
Hsp27 belongs to the small heat shock proteins and func-
tions in an ATP-independent fashion. There are three
phosphorylation sites of Hsp27, including serine 15, ser-
ine 78 and serine 84 [21]. The phosphorylation of Hsp27
leads the dissociation of the large Hsp27 chaperon com-
plex into small Hsp27 dimer or tetramer and changes the
chaperon activity into a cell signaling player [22]. The
phosphorylation of Hsp27 has been demonstrated to con-
tribute to many cellular behaviors of cancer, such as actin
filament dynamics, cell survival, cell migration/invasion
and cell differentiation [21]. For example, attenuation of
Hsp27 phosphorylation by the specific microtubule inhi-
bitor, KIRBB3, leads to a decrease in tumor cell migration
and invasion [22]. In addition, Bausero et al.h a v e
demonstrated that the silencing of Hsp25 expression
abrogated the migration potential of 4T1 cells through
repression of matrix metalloproteinase 9 and up-regula-
tion of tissue metalloproteinase 1 [23]. The phosphoryla-
tion of Hsp27 often affects its interaction with the target
proteins. For example, the binding of tropomyosin with
Hsp27 was increased when Hsp27 was phosphorylated
[24]. In our study, Hsp27 phosphorylation in AS-B145
and AS-B244 was found at all three of these serine sites
(unpublished observation). The role of Hsp27 phosphory-
lation in self-renewal or EMT character of BCSCs should
be further investigated by overexpression of phosphor-
mimic (serine change to aspartic acid) or phosphor-dead
(serine change to alanine) mutants.
Hsps are widely known for their cytoprotection func-
tions in cancer cells [25]. These mechanisms include
their molecular chaperone activity, anti-apoptosis func-
tion and influence on the stability of client proteins [26].
Many Hsp27 client proteins have been reported pre-
viously [27]. For example, Hsp27 binds with cytochrome
c to inhibit apoptosis [28]. In our study, knockdown of
Hsp27 in breast cancer cells did not induce marked cell
death at 48 h, which was the time point at which we ana-
lyzed the ALDH+ population in both AS-B145 and AS-
B244 cells, but slowed the cell growth (Additional file 1
Figure S3). It suggests that the clients of Hsp27 in BCSCs
possibly include proteins which are not related to apop-
tosis. It has been reported that Hsp27 enhances the
degradation of ubiquitinated proteins, such as phosphor-
IBa, by 26S proteasome [19]. Here we also found that
Hsp27 could regulate the nuclear translocation and activ-
ity of NF-B in ALDH+ BCSCs through increasing the
expression of IBa (Figure 6). The 26S proteasome med-
iates protein degradation not only in IBa,b u ta l s oi n
p53, which is a suppressor of self-renewal of BCSCs [29].
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Page 9 of 13Figure 6 Knockdown of Hsp27 decreased the activity of NF-B in BCSCs.( A) AS-B145 or ALDH+ AS-B244 cells were transfected with
negative control siRNA (Ctrl) or Hsp27 siRNA (KD) for 24 h or 48 h and total proteins were harvested to detect the expression of IBa,
phosphor-IBa (p-IBa), Hsp27 and b-actin by Western blot. Inserted values indicated relative proteins expression in comparison with ctrl siRNA.
(B) AS-B145 or ALDH+ AS-B244 cells were transfected with negative control siRNA (Ctrl) or Hsp27 siRNA (KD) for 48 h and nuclear (Nuc) and
cytosolic (Cyto) proteins were isolated to detect NF-B, histone H1, Hsp27 and b-actin by Western blot. Inserted values indicated relative proteins
expression in comparison with ctrl siRNA. (C) AS-B145 or ALDH+ AS-B244 cells were co-transfected with NF-B reporter vector, Renilla luciferase
vector and negative control siRNA (ctrl-si)/or Hsp27 siRNA (si-Hsp27) for 48 h. Luciferase activity was determined by dual luciferase assay. Data
were presented as relative luciferase activity of ctrl siRNA. *, P < 0.05. (D) AS-B145 or AS-B244 cells were treated with JSH-23 (20, 10 or 5 μM) or
0.1% DMSO for 48 h and ALDH+ population were determined by ALDEFLUOR assay. Data were presented as relative percentage of DMSO. *, P <
0.05; #, P < 0.01. ALDH, aldehyde dehydrogenase; BCSCs, breast cancer stem cells; NF-B, nuclear factor kappa B
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Page 10 of 13Figure 7 Restoring NF-B activity attenuates the suppressive effect of Hsp27 knockdown in ALDH+ breast cancer cells. AS-B145 or AS-
B244 cells were transfected with negative control siRNA (Ctrl-siRNA, 100 nM), ctrl-siRNA (50 nM)+si-Hsp27 (50 nM) or si-Hsp27 (50 nM) +si-IBa
(50 nM) for 48 h. (A) The expression of Hsp27 and IBa was determined by Western blot. Inserted values indicated relative expression in
comparison with ctrl-siRNA. (B) The NF-B activity was determined by co-transfected with NF-B-Luc reporter vector (0.5 μg) and RLuc (0.05 μg)
vector. The results were presented as relative luciferase activity to ctrl-siRNA. (C, D) The percentage of ALDH+ population among groups was
determined by ALDEFLUOR assay. DEAB was used to set the cutoff line for ALDH+ cells. The quantitative results were presented as relative
percentage of negative control siRNA (ctrl-siRNA) group and were shown in bar graph (D). *, P < 0.05; #, P < 0.01. ALDH, aldehyde
dehydrogenase; NF-B, nuclear factor kappa B.
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Page 11 of 13Lagadec et al. have demonstrated that BCSCs could be
defined as cells with low 26S proteasome activity [30].
Our observations suggest that Hsp27 might enhance the
degradation of self-renewal suppressors in BCSCs, which
are cells with low proteasome activity in their cellular
microenvironment. It is well known that NF-Bi sa n
important transcriptional factor in the expression of
cytokines, including IL-6 and IL-8. High serum IL-6 con-
centration has been reported to be correlated with poor
prognosis for breast cancer [31]. IL-6 mRNA expression
has been shown to be evaluated in mammospheres
derived from malignant mammary tissues [32]. Moreover,
IL-6 autocrine loop could trigger a Notch-3/Jagged-1
pathway to enhance the growth and aggressive pheno-
types of mammospheres derived from malignant mam-
mary tissue or MCF7 breast cancer cell line [32]. On the
other hand, IL-8/CXCR1 signal has been demonstrated
to maintain the self-renewal of BCSCs [33]. IL-8 expres-
sion was increased in mammospheres and treatment of
IL-8 increased the mammosphere number of breast can-
cer cells and blockage of CXCR1 signaling by repertaxin
reduced chemoresistance of BCSCs [33]. Because Hsp27
regulates the activity of NF-B in BCSCs, it is possible
that Hsp27 is also involved in the regulatory function of
IL-6 and IL-8 on BCSCs.
HSPs have also been found on cell membrane. Glucose-
related protein (GRP)-78, a member of Hsp70 family, has
been demonstrated as a novel marker of CSCs of head and
neck squamous carcinoma cells (HNSCC) [34]. Knock-
down of GRP78 reduced self-renewal ability and expres-
sion of stemness genes but induced differentiation and
apoptosis of CSCs of HNSCC [34]. In mouse breast cancer
4T1 study, Hsp25 (an Hsp27 homolog in mouse) could be
detected on the cell surface. With FACS, 4T1 cells with
surface Hsp25+Hsp70- displayed high tumorigenicity and
metastatic ability when compared with surface Hsp25+
Hsp70+ cells [35]. It suggests that surface Hsp25+ Hsp70-
could serve as a marker of 4T1 CSCs. Whether Hsp27
could also be expressed on the cell surface of breast cancer
cells and as a novel marker for BCSCs, should be investi-
gated further.
Conclusions
In conclusion, our present study demonstrates that Hsp27
participates in the maintenance of BCSCs, which were
determined by mammosphere forming capability and cell
migration potential of breast cancer cells and ALDH+
BCSCs. Hsp27 also is involved in the activation of NF-B
in breast cancer cells and ALDH+ BCSCs by regulation of
IBa degradation. These mechanisms demonstrate how
Hsp27 contributes to the maintenance of BCSCs. Hsp27
inhibitors, such as quercetin, can potentially be developed
in chemoprevention of breast cancer.
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